Molecular Partners Presented Initial Data From First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting
Molecular Partners Presented Initial Data From First Four Dosing Cohorts of Ongoing Phase 1/2a Trial Of MP0533 For Patients With Relapsed/Refractory AML And AML/MDS At 2023 ASH Meeting
Molecular Partners 在 2023 年 ASH 會議上公佈了正在進行的針對復發/難治性急性髓細胞白血病和急性髓細胞白血病患者的 MP0533 1/2a 期試驗的前四個給藥隊列的初步數據
Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today presented positive initial clinical data from its ongoing Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager, in a poster at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These data, which highlight encouraging initial safety and antitumor activity, expand upon those previously disclosed in the conference abstract.
Molecular Partners AG（SIX：MOLN，納斯達克股票代碼：MOLN）是一家開發一種名爲DarPin療法的新型定製蛋白質藥物的臨床階段生物技術公司，今天在第65屆美國血液學會（ASH）年會和博覽會上發佈的海報中公佈了其正在進行的新型四特異性T細胞參與者 MP0533 的1/2a期試驗的積極初步臨床數據。這些數據突顯了令人鼓舞的初始安全性和抗腫瘤活性，並對先前在會議摘要中披露的數據進行了擴展。
- Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported responder in dose range three
- MP0533 monotherapy continues to demonstrate an acceptable safety profile across the first four dosing cohorts, with no dose-limiting toxicities observed
- Phase 1/2a trial remains ongoing with patients being enrolled in fifth of seven planned dose-escalation cohorts
- 在早期的 MP0533 劑量遞增隊列中觀察到初始抗腫瘤活性，除了先前報告的劑量範圍爲三的反應者外，在劑量範圍 4 中觀察到先前未公開的完全反應 (CR)
- 在前四個給藥組中，MP0533 單一療法繼續顯示出可接受的安全性，未觀察到劑量限制毒性
- 1/2a期試驗仍在進行中，在七個計劃劑量遞增隊列中，有五分之一的患者入組